Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005
April 16th, 2007
Transition Therapeutics Inc. ("Transition") (TSX: TTH) announced today that the United States Food and Drug Administration ("FDA") has granted Fast Track designation to investigational drug candidate AZD-103/ELND005, being developed in collaboration with Elan Corporation, plc. ("Elan") (NYSE: ELN) for the treatment of Alzheimer's disease. AZD-103/ELND005 is currently being evaluated in multiple Phase I clinical studies, and the companies anticipate starting Phase II clinical studies around the end of 2007. "The decision by the FDA is very encouraging news for Alzheimer's disease patients and their families, and we believe it reflects the considerable potential for...
Source: Clinical Trials Week (2007-04-16)
|
